Fourth quarter, 1 February - 30 April 2022
Net sales amounted to 3 593 (3 816) kSEK.
Operating result (EBIT) amounted to – 3 576 (-2 743) kSEK.
Net result for the period amounted to -3 721 (-3 051) kSEK.
Earnings per share amounted to -0.92 (-1.41) SEK. Earnings per share after dilution amounted to  -0.92 (-1.41) SEK.
Cash flow from operations before investment activities amounted to -1 555   (-485) kSEK.
After the reporting period: We have announced a new collaboration with Lund University, in the field of precision diagnostics to develop solutions for improved clinical diagnostics of bladder cancer. Bladder cancer is the third classifier model co-operation launched by Qlucore in the area of solid tumors.


1 May - 30 April 2021/2022
Net sales increased to 14 118 (12 943) kSEK.
Operating result (EBIT) amounted to  -11 491 (-5 565) kSEK.
Net result for the period amounted to -11 663 (-6 035) kSEK.
Earnings per share amounted to -3.50 (-3.05) SEK. Earnings per share after dilution amounted to -3.50 (-3.05) SEK.
Cash flow before investment activities amounted to -6 806 (-1 082) kSEK.
The Board’s proposal to the general meeting, is to not distribute any dividend for the financial year.

CEO’s statement
Qlucore continued to develop positively during the quarter. We have, for example, signed another customer agreement in the cancer analysis segment. The Department of Pathology and Experimental Cancer Research at Semmelweis University in Budapest will use our Qlucore Insights software to improve how to diagnose acute leukemia. Sales in the data analysis segment continue to develop well and the Qlucore Omics Explorer software is currently used in more than 200 organizations, both in academia and in industry.

Net sales during the fourth quarter amounted to SEK 3,593 thousand and for the full year to SEK 14,118 thousand, which is an increase of 9% compared with the previous financial year. The data analysis segment still accounts for the largest share of net sales. The investments in our growth area of cancer diagnostics continue. We are paying great attention to this area, and it is also in this area that we are investing resources and funds, completely in accordance with the plan. These investments involve higher costs, which are reflected in the result.

The Corona pandemic continued to affect sales and marketing, partly due to longer customer decision-making processes among our customers, and partly by limiting our opportunities to reach new customers. The war in Ukraine has not affected us directly as we do not have either customers or suppliers in Russia, Belarus or Ukraine. At the end of the quarter, however, we see a positive development and were able to conduct several physical meetings with customers again, even though sales work was mainly done digitally. A large proportion of the total marketing and sales efforts are aimed at the data analysis segment, however the work towards potential customers in the cancer diagnostics segment is gradually increasing. The latter work is now led by Erik Söderbäck, head of sales in the cancer diagnostics segment. There is great interest in our products and as the world opens, we expect to be able to further intensify market development efforts.

The development work continues to focus on two areas, partly on new software versions for the data analysis segment, and partly on improvements to the Qlucore Insights/Diagnostics platform for cancer diagnostics. Together with partners, we continue to develop models for the diagnosis of lung cancer and breast cancer, which complements our application for leukemia.

Obtaining the CE mark for Qlucore Diagnostics is a milestone in which extensive work to prepare the application in accordance with the IVDR Regulation is ongoing. However, there is some uncertainty regarding the schedule because the application requires approval of a "Notified Body" and there is a lack of capacity for such in the industry.

Internally, we have formed a new powerful management team consisting of myself, Erik Söderbäck (Sales diagnostics), Ulf Ahlfors (Development), Per Nordqvist (Quality), Cecilia Grotte (Finance) and Marie Gralén (Staff, part-time consultant). Of this management group, four were recruited during the year. The fact that we have not only succeeded in attracting these qualified employees but also expanded our development organization, is further proof that we are an exciting company, at the forefront, and thus an attractive employer. It is with great confidence that I look forward to the next financial year and the works to continue to develop Qlucore into a successful company.